Results 111 to 120 of about 1,470 (198)

Preliminary Observations on the Efficacy of Efgartigimod Therapy in Autoimmune Nodopathy

European Journal of Neurology
ABSTRACTBackgroundAutoimmune nodopathy exhibits suboptimal responses to conventional immunotherapies. This study investigates the efficacy and safety of efgartigimod, a neonatal Fc receptor blocker, in this condition.MethodsA prospective single‐center study enrolled four antibody‐confirmed autoimmune nodopathy patients receiving weekly efgartigimod (10 
Hongfei Tai, Songtao Niu, Hua Pan, Fan Jian, Zhenxian Hu, Na Chen, Ying Wang, Zaiqiang Zhang   +7 more
openaire   +2 more sources

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study

Therapeutic Advances in Neurological Disorders
Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG.
Geke Zhu, Han Zhou, Wanying Wang, Yongbo Ma, Xiangtao Nie, Wenjing Qi, Lei Hao, Xiuming Guo   +7 more
doaj   +1 more source

Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis

Clinical and Translational Medicine
Background Myasthenia gravis (MG) is an autoimmune disease predominantly driven by autoantibodies targeting acetylcholine receptor (AChR), resulting in muscle weakness.
Hui‐Ning Li, Jingjing Liu, Xiao‐Yu Huang, Lijie Zhu, Zhirui Liu, Chun‐Sheng Yang, Bo Zhang, Shixiong Huang, Fu‐Dong Shi, Zhigang Cai, Chao Zhang   +10 more
doaj   +1 more source

Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barré syndrome: a retrospective study. [PDF]

Front Immunol
Liu C, Wang K, Zhang S, Gao N, Xu G, Qi F.   +5 more
europepmc   +1 more source

Preliminary observations on the efficacy of efgartigimod in anti-LGI1-associated autoimmune encephalitis. [PDF]

Ther Adv Neurol Disord
Zuo JW, Dai YY, Liu WJ, Zhang JY, Shao XQ, Wang Q, Lv RJ.   +6 more
europepmc   +1 more source

Myasthenia Gravis Exacerbation Potentially Triggered by Exogenous Thymus Administration [PDF]

, 2022
Hove, Jason, Sangalang, Michelle
core  

Evaluación de la eficacia y seguridad de anticuerpos monoclonales inhibidores del receptor neonatal Fc en la miastenia gravis [PDF]

Antecedentes La miastenia gravis (MG) es una enfermedad autoinmune rara que afecta la transmisión neuromuscular, provocando debilidad muscular fluctuante.
González García, Mónica
core  

Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review. [PDF]

Am J Case Rep
Liu ZH, Duan LM, Fang XZ, Jiang W, Sun SW, Shang Y, Huang CL, Yuan Y.   +7 more
europepmc   +1 more source

Correction to: Efgartigimod: First Approval

Drugs, 2022
openaire   +1 more source

Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis. [PDF]

Front Immunol
Li N, Zhang Y, Liu L, Jin Y, Zhao L, Zhu S, Li Y, Ma B, Peng J, Yang J, Li Q, Yang X.   +11 more
europepmc   +1 more source